Moxaquin contains Moxifloxacin which is used to treat a variety of bacterial infections. This medication belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treat only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Each film coated tablet of Moxaquin contains 400 mg of Moxifloxacin.

Adults

 Community Acquired Pneumonia

Moxaquin is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma

pneumoniae, or Chlamydophila pneumoniae.

MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

Skin and Skin Structure Infections: Uncomplicated and Complicated

Moxaquin is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.

Moxaquin is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae

Complicated Intra-Abdominal Infections

Moxaquin is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species.

Plague

 Moxaquin is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. Therefore, this indication is based on an efficacy study conducted in animals only.

Acute Bacterial Sinusitis

Moxaquin is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.

Acute Bacterial Exacerbation of Chronic Bronchitis

Moxaquin is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.

Children and adolescents

Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established.

Children have a higher chance of getting bone, joint, and tendon (musculoskeletal) problems while taking fluoroquinolone antibiotic medicines.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy Category C. Because no adequate or well-controlled studies have been conducted in pregnant women, Moxaquin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Based on animal data may cause fetal harm.

Moxifloxacin is excreted in the breast milk of rats. Moxifloxacin may also be excreted in human milk. Because of the potential for serious adverse reactions in infants who are nursing from mothers taking Moxaquin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Adults and Children 18 years and over:

The dose of moxifloxacin is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection.

• Community Acquired Pneumonia: The duration of the treatment is 7 to 14 days.
• Uncomplicated Skin and Skin Structure Infections (SSSI): The duration of the treatment is 7 days.
• Complicated SSSI: The duration of the treatment is 7 to 21 days.
• Complicated Intra-Abdominal Infections: The duration of the treatment is 5 to 14 days.
• Plague: The duration of the treatment is 10 to 14 days.
• Acute Bacterial Sinusitis (ABS): The duration of the treatment is 10 days.
• Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB): The duration of the treatment is 5 days.

Administer Moxaquin tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution.

Moxaquin tablets can be taken with or without food, drink fluids liberally.